Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainProgressive multifocal leukoencephalopathy: clinical and molecular aspectsProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarateSafety and diagnostic value of brain biopsy in HIV patients: a case series and meta-analysis of 1209 patients.PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review.Progressive multifocal leukoencephalopathy in HIV-1 infection.Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature ReviewNatalizumab in the treatment of multiple sclerosisDetection of human herpesviruses in the cerebrospinal fluid from patients diagnosed with or suspected of having progressive multifocal leukoencephalopathyProgressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.Metabolic profile of PML lesions in patients with and without IRIS: an observational studyNeurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and TreatmentCNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Critical care of persons infected with the human immunodeficiency virus.Central nervous system immune reconstitution inflammatory syndrome.An evidence-based review of natalizumab therapy in the management of Crohn's disease.Human polyoma viruses and disease with emphasis on clinical BK and JC.Immune surveillance and response to JC virus infection and PML.Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?The human JC polyomavirus (JCPyV): virological background and clinical implications.Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS).Progressive multifocal leukoencephalopathy in an immunocompetent patient.Assessment of infection with polyomaviruses BKV, JCV and SV40 in different groups of Cuban individuals.Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.High-resolution melting analysis for mutation scanning in the non-coding control region of JC polyomavirus from patients with progressive multifocal leukoencephalopathy.Progressive multifocal leukoencephalopathy, a rare but devastating disease in AIDS patients.Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.JC -- a forgotten foe or a foe to be forgotten?JC virus infection of the brain.Transformed occupational prospects for HIV-associated brain syndromes.Ataxia and HIV: clinicopathologic correlations in a case of HIV-associated cerebellar leukoencephalopathy.Progressive multifocal leukoencephalopathy as an AIDS-defining condition in a patient with high CD4+ T-lymphocyte count.
P2860
Q21285083-877FF105-49BF-491E-B924-8199BDC8C79FQ24619923-287C592F-D5BA-48D4-A32F-9ECA03247BFEQ26858968-DADD29A4-29A0-4E90-91ED-708E12CFF221Q28083338-472A208D-8BB2-4968-921D-93BC455B766BQ30251971-5FC0EA0E-956E-4F4A-85F7-D5163930C397Q30613846-EEE161DB-DB15-4713-8220-021BBEAF6122Q30778800-5E78C520-2B89-4B86-BE29-4DD119A20103Q33506561-E2784BF4-E439-488B-9A45-82656F5CE26FQ33715659-A94A184A-C7CC-462B-9E28-091A6E460824Q34409340-2594D154-25AC-4F7E-AD81-AB370449A016Q35065104-05EDE9F6-6613-4590-80F5-4117D53ADB55Q35701501-57037F53-7347-4E1C-8DDE-02B1C95E6EC5Q36198630-2A709A68-EBF2-405F-A823-0B03195F9BD4Q36330202-8C11E744-15F0-4865-BD4E-5ABDE2114E76Q37041199-04255DC4-F8F7-404C-AD12-5462379A0439Q37205963-E7CC847C-C7A8-44F2-AAD0-355C316CC8FAQ37442512-7898C5E5-1822-43B2-B9F2-268CA7CC6E49Q37462968-361D9E9E-9DB3-4B8B-B948-995913032FEFQ37671117-7359D0B3-7C18-44A0-AF95-B0C487A5BFABQ37678580-29169109-B0B7-4B6A-ACC2-49B1E7FA1F9DQ37778944-C1CC7B8D-4DB5-4397-B69B-72B4F9D04019Q38115572-B5447AE7-C764-4728-BE1E-25161C1F332EQ38690896-1CA15931-20BF-4F52-AB10-32405C26550CQ38717292-4404529B-7072-415C-A554-79456AC3DD3BQ39220719-9067BFA4-5AFB-4CC6-8B0F-2547ED976F1FQ41282310-550CAD85-8D85-467D-98EA-6AA7E29D154DQ41906877-82DEE43B-9F5A-4BAE-8AA9-AA56C44D61B2Q42231270-A528C696-9500-4D88-9CFE-8FB2A800B13AQ42246913-A87DDF8D-0505-444B-9558-937E9CA5C2FBQ42251011-90AC2119-CF96-4C31-870A-F8B066C78C4FQ44741202-81E22C44-5CB8-41FF-BA0A-8A10214B3062Q45377474-9CFF631F-E7B2-4927-B441-41E65561685AQ48014749-25F2A5D3-B6DA-4FD5-96BE-AE30E0C63FEAQ48743220-E496D7DE-9770-45CF-9CB1-2E68B0D59460Q53242999-958972AD-17C6-42E3-A99E-0356EA338FF1
P2860
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@ast
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@en
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@nl
type
label
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@ast
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@en
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@nl
prefLabel
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@ast
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@en
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@nl
P2860
P50
P921
P1476
Reduced rate of diagnostic pos ...... potent antiretroviral therapy.
@en
P2093
Angela Marzocchetti
P2860
P304
P356
10.1128/JCM.43.8.4175-4177.2005
P407
P577
2005-08-01T00:00:00Z